Certara, Inc. (CERT)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$7.94-2.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Revenue growth of 0% to 4% excluding divested business: FY26 rev +1.0% vs 0%-4% target.
Certara focuses on its core drug research software. Revenue may grow 0% to 4% in 2026. Profit margins should stay near 30% to 32%. The company sold a non-core business for $85 million plus earn-outs.
Earnings have missed estimates twice recently. Revenue growth is weak and guidance was cut. The CFO left, which may hurt execution.
The price is about 44% above our fair value near $5. Analysts expect about 2% revenue decline. We see risk in growth and profit margins.
Breaks if: Additional key executives leave within next 4 quarters
Breaks if: Margin falls below 30% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround play with a focus on stabilizing revenue and margins. The current thesis state is intact, supported by recent financial performance, but there are concerns about future guidance and market conditions.
The market seems to have priced in a low level of fragility, suggesting that expectations are somewhat aligned with current performance. However, there is an expectations gap, indicating that the market may not fully account for potential risks or future earnings misses.
Management has set a revenue growth target of 0% to 4% for 2026, which they are currently on track to achieve. However, the company has a history of earnings misses, which raises concerns about its ability to meet future expectations.
The thesis hinges on management's ability to maintain guidance and execute on their priorities, particularly in light of potential sector momentum from peers. Additionally, macroeconomic factors, such as job growth and recession fears, could significantly impact performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Sustain full-year adjusted EBITDA margin in the range of approximately 30% to 32% for continuing operations excluding the divested Regulatory and Medical Writing business.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin was 32% in 2025 and management expects approximately 29% to 31% margin for continuing operations in 2026 excluding the divested business. The margin guidance reflects a slight decline but remains within the targeted range, indicating management is maintaining cost discipline amid restructuring.
“Full year 2026 adjusted EBITDA margin for Continuing Operations is expected to be approximately 29% to 31%.”
“Full year 2026 Adjusted EBITDA margin is expected to be approximately 30% - 32%.”
“Full year adjusted EBITDA margin to be approximately 30-32%.”
Breaks if: Revenue growth falls below 0% in FY26
Achieve full-year revenue growth of 0% to 4% on a comparable continuing operations basis, excluding the Regulatory and Medical Writing business divested in Q2 2026.
Stated as a priority in 3 of last 3 quarters. Revenue was $418.8M in 2025 and continuing operations revenue guidance for 2026 is $367M to $382M reflecting 0% to 4% growth excluding the divested Regulatory and Medical Writing business. Management has consistently reaffirmed this growth range, and the trajectory is delivering with modest growth in software offsetting services declines.
“We continue to expect full-year revenue growth of 0% to 4% on a comparable continuing operations basis.”
“Revenue growth expectations of 0% - 4% excluding the Regulatory and Medical Writing Business.”
“Full year 2026 revenue is expected to grow in the range of 0-4%.”
Over the next 1 to 3 years, CERT's performance will depend on management execution and external economic conditions. Not investment advice.